Vaccine maker Moderna said Thursday it expects to have between 100 million and 125 million doses of its coronavirus vaccine available by the first quarter of 2021, with most of those designated for the US market.
The company has applied for emergency use authorization for its vaccine from the US Food and Drug Administration and FDA advisers are scheduled to discuss the application Dec. 17. Moderna has also applied to European drug regulators for conditional approval.
“Today, Moderna re-affirmed its expectation of having approximately 20 million doses available in the U.S. by the end of 2020,” the company said in a statement.
“Additionally, the Company expects to have between 100 million and 125 million doses available globally in the first quarter of 2021, with 85-100 million of those available in the U.S. and 15-25 million of those available outside of the U.S. These expected first quarter doses are inclusive within the 500 million to up to 1 billion doses that the Company expects to manufacture globally in 2021.”
The Moderna vaccine requires two doses per person, with the shots spaced four weeks apart.